Soluble Therapeutics Acquired by CytoBioscience more

Young Living Essential Oils Partners with TFS Sandalwood Farms more

Beaufort Memorial Using Xenex Germ-Zapping Robot to Destroy Pathogens That Can Cause Hospital-Acquired Infections more

DNAtrix to Present Clinical Data at the 21st Annual Meeting of the Society for Neuro-Oncology more

Cartersville Medical Center Unveils Xenex Germ-Zapping Robot more

DNAtrix enters into license agreement with University of Florida to develop new oncolytic virus platform more

DNAtrix Licenses Myxoma Virus for New Immunotherapy Platform more

Supportive Data for the Use of Santalis Pharmaceuticals’ East Indian Sandalwood Oil (EISO) for the Treatment of Psoriasis is Presented at International Conference more

Santalis Pharmaceuticals Obtains FDA Allowance To Start A Phase 2 Clinical Study For The Treatment Of Mild To Moderate Atopic Dermatitis (AD) more

DNAtrix Announces First Patients Treated in Phase 2 Trial with DNX-2401 and KEYTRUDA more

Robotics: Germ-Zappers Are Saving Lives more

DHR first in RGV with xenon UV disinfection systems more

neoSurgical® Announces CE Mark Approval of the neoClose® Laparoscopic Port Closure Device more

Germ-zapping robot named 'Gronk' helped kill MRSA at Mass. high school more

Doctors Hospital at Renaissance is First in Rio Grande Valley to Deploy Xenex Germ-Zapping Robots more

Bio2 Medical's Angel Catheter successfully placed in first two patients more

Cardiovate Develops First Bioabsorbable Vascular Graft more

Funding San Antonio’s Biotech Ecosystem more

A biotech groups to share in major military contract to manufacture stem cells more

Robot disinfecting rooms at Life Line Hospital in Wintersville more

Life Line Hospital is the First Long Term Acute Care Hospital in Ohio to Enhance Patient Safety by Deploying a Xenex Germ-Zapping Robot more

Robots show Marin, Sonoma hospitals the light on disinfection more

Santalis Pharmaceuticals Announces Issuance of Patent for the Use of Sandalwood Oil to Treat Cancers more

Santalis Pharmaceuticals Initiates a Phase 2 Study of Mild, Moderate and Severe Atopic Dermatitis - Enrolls First Patient Into Its Australian Clinical Trial Site more

With Scaffold for Regenerating Arteries, Cardiovate Raises $350,000 more

Bluegrass Vascular Secures CE Mark Approval and Announces Successful Commercial Use of The Surfacer® Inside-Out® Access Catheter System more

Bio2 Medical® Closes on $3 Million of Venture Debt Financing more

Tropical Forestry Services prepares for first Indian sandalwood shipment to China more

Bio2 Medical® Announces 510(k) Clearance from the FDA for the Angel® Catheter, the First Ever Prophylactic Use Indication for a Medical Device for Pulmonary Embolism more

International perfumery competition winner tours Indian sandalwood plantations in the Kimberley more

SA biotech firm drawing global interest year after moving from Germany more

TFS Corporation makes bond offer more

New robot system at USC Verdugo Hills Hospital uses UV light to disinfect hospital rooms more

DNAtrix wins $2 million FDA grant for cancer immunotherapy more

DNAtrix Awarded FDA Orphan Products Development Grant for DNX-2401 more

TFS Corporation - July 2016 Update more

StemBioSys reaches European distribution agreement for its products more

BRIEF-Diamyd Medical: Cellaviva appointed European distributor for StemBioSys more

DNAtrix Receives European Medicines Agency PRIME Designation more

DNAtrix Announces Successful Intratumoral Delivery of DNX-2401 via Alcyone's MEMS Cannula for the Targeted Treatment of Recurrent Glioblastoma more

Australia forestry company TFS Corp gets two ratings upgrades more

Tour of Texas: Valence, Stellarray, Flux Farms, A&M, StemBioSys more

StemBioSys reaches distribution agreement for its products in South Korea more

Camden Clark Medical Center Introduces Newest Xenex Germ-Zapping Robot more

MPR Client Innovative Trauma Care Wins Gold at 2016 Medical Design Excellence Awards more

Santalis Pharmaceuticals Announces Positive Results From a Study Using 10% East Indian Sandalwood Oil (EISO) Serum Formulation for the Treatment of Mild-to-Moderate Plaque Psoriasis more

Texas among top states in foreign investments more

How Your Family Drives Business Decisions more

StemBioSys enters distribution agreement for its products in Japan more

San Antonio biotech firm takes big step toward global expansion more

Vidant Edgecombe Hospital adds Xenex Germ-Zapping Robot to reduce HAIs more

This hospital spent $300,000 on giant, superbug-killing robots more

Santalis Announces First Subject Enrolled in Phase 2 Trial of East Indian Sandalwood Oil (EISO) to Treat Mild to Moderate Plaque Psoriasis more

SA biotech company backing fed stem cell bill to cut red tape from regulatory pathway more

Bexar County added 4,350 jobs last year, study says more

Springfield Clinic unveils Xenex Germ-Zapping Robot for infection control more

San Antonio venture capital funding fell last year more

neoSurgical Limited Expands Indications For neoClose Device more

Bio2 Medical Closes Series D Preferred Stock more

TFS undertakes $60 million placement more

Bluegrass Vascular Technologies’ catheter system used on first patient more

Cytocentrics refunds $100,000 in economic development funds to city more

Bluegrass Vascular Technologies Announces First Clinical Use of the Surfacer® Inside-Out® Access Catheter System in Europe. more

Long-term acute care facility in California implements Xenex germ-zapping robot more

Robotic housekeeper disinfects the rooms at Modesto hospital more

Aerin Medical raises $16.7M, adds new board members more

Brokers Sniff Sweet Potential In TFS Corp more

East Indian sandalwood oil (EISO) is the key ingredient in these grooming products for dogs more

Santalis Pharmaceuticals Completes the Spin-Off of Roxy’s Remedies Inc. more

TFS Corporation - January 2016 Update more

DNAtrix's Oncolytic Immunotherapy, DNX-2401, Awarded EU Orphan Medicine Designation more

Strategic partnering deal with Cytocentrics more

Cytocentrics CEO: San Antonio to get big boost from new deal more

GhostBuster the Lab Mix Reviews Roxy’s Remedies Pure Relief Spray Gel more

Avera McKennan Addresses Patient Safety with Germ-Zapping Robots more

Santalis Pharmaceuticals Announces Positive Results from a Study of Pediatric Patients with Eczema more

Santalis announces positive results for pediatric atopic dermatitis treatment more

Here’s why the TFS Corporation Limited share price soared 28% today more

Cytocentrics gaining traction in San Antonio more

The Drugstore Acne Fighters Dermatologists Swear By more

neoSurgical® Begins Postmarket Surveillance Study more

Santalis Announces First Subject Enrolled in Phase 2 Trial of East Indian Sandalwood Oil to Treat Pediatric Molluscum contagiosum

SAN ANTONIO--(BUSINESS WIRE)--Santalis Healthcare Corporation (formerly ViroXis Corporation), a wholly owned subsidiary of TFS Corporation, Ltd. (ASX:TFC), is pleased to announce that the first subject has been enrolled in a double-blind, placebo-controlled, randomized Phase 2 trial for the treatment of Molluscum contagiosum, testing a topical formulation of the company’s novel botanical drug candidate, East Indian Sandalwood Oil (EISO).

Santalis Healthcare Corporation is a clinical-stage biopharmaceutical company developing innovative EISO-based therapies for viral diseases of the skin. A single dose level of the EISO-based botanical drug candidate is being evaluated in this clinical study to assess safety and efficacy in up to 60 pediatric subjects. The on-going trial, which is being conducted at Texas Dermatology and Laser Specialists in San Antonio, TX, is expected to be completed in 2016.

Molluscum contagiosum virus (MCV), a member of the poxvirus family, is responsible for a highly contagious skin infection that occurs predominately in children. The hallmark of MCV infection is the appearance of numerous, raised, unsightly lesions on the skin which can cover large areas of the body, including the face, neck, armpit, arms, and hands. The lesions may become itchy, sore, red and swollen if untreated. MCV infection is prevalent throughout the United States, is spread through skin contact and accounts for approximately 1% of all diagnoses of skin disorders. There is currently no effective prescription treatment for this condition.

"Molluscum contagiosum is highly contagious and the virus infects large numbers of children each year,” commented Dr. John C. Browning, Pediatric Dermatologist and Principal Investigator for the trial. "When a child has an infection, it can spread to friends and family and he or she often can't participate in sports or social activities due to the contagious nature of the disease. Current treatment options are often painful and there is a high unmet medical need for new products that are effective, safe and non-invasive to treat this large patient group."

ABOUT MOLLUSCUM CONTAGIOSUM
Molluscum contagiosum is a viral infection of the skin caused by a DNA poxvirus Molluscum contagiosum virus (MCV). This virus is spread by skin contact and has a higher incidence in children, sexually active adults, and those who are immunodeficient. Picking or scratching may lead to further infection or scarring, and in about 10% of the cases, eczema develops around the lesions.

MCV treatment options are invasive, requiring tissue destruction and attendant discomfort. Surgical treatments include using liquid nitrogen to freeze and destroy lesions, as well as scraping them off with a curette. Scarring and loss of skin color can complicate both these treatments.

ABOUT SANTALIS
Santalis Healthcare Corporation (formerly known as ViroXis Corporation) is a wholly owned subsidiary of TFS Corporation, Ltd. (ASX: TFC). ViroXis, and its sister company, Santalis Pharmaceuticals, were acquired by TFS in July 2015 and are developing over-the-counter and prescription products that utilize TFS’ cultivated, sustainable, pharmaceutical-grade East Indian Sandalwood Oil. TFS’ prescription drug development programs are focused in oral health and dermatology, where EISO’s well documented safety and anti-infective, anti-proliferative and anti-inflammatory properties are well suited to a number of prevalent and under-served conditions. In addition to the pediatric Molluscum contagiosum study, TFS has ongoing Phase 2 studies in oral mucositis, pediatric atopic dermatitis (eczema) and psoriasis, and is preparing to initiate a Phase 3 study for pediatric HPV skin warts.

ABOUT INDIAN SANDALWOOD
Indian sandalwood has a history as a tradeable commodity spanning thousands of years, but is now endangered due to the illegal harvest of wild trees throughout the world. As a result, Indian sandalwood is the world’s most expensive tropical hardwood. Indian sandalwood oil is a globally important ingredient in fine fragrances, cosmetics and toiletries, Indian consumer products and is used for traditional medicinal purposes (Ayurvedic and Chinese medicine). The wood is used for high quality carvings and artefacts and religious worship in the Hindu and Buddhist faiths. The global pharmaceutical market has the potential to be a significant consumer of Indian sandalwood.

Contacts
Santalis Healthcare Corporation
Ian Clements, COO, 210-399-2315
Mobile: 210-643-8847
Ian@santalispharma.com

Source: http://www.businesswire.com back

BiO2 Medical Reports Positive Advancement of the Series D Round of Funding more

Germany’s Axiogenesis to collaborate with new San Antonio biotech company more